Viscient Biosciences
San Diego–based biotechnology company that develops and applies human three-dimensional tissue models combined with multi-omics analysis to discover and progress therapeutic candidates, with an initial focus on non-alcoholic steatohepatitis (NASH). Uses primary human cells and 3D tissue reconstruction to model disease biology in vitro, identify disease-driver genes and advance drug discovery programs toward preclinical and early clinical stages.
Industries
Nr. of Employees
small (1-50)
Viscient Biosciences
Products
Preclinical drug candidate discovered using 3D human liver model
A therapeutic candidate identified and progressed to preclinical development using human 3D liver disease models and multi-omics target discovery workflows.
In-licensed clinical-stage drug candidate (planned Phase 2)
An externally sourced therapeutic candidate intended for progression into Phase 2 clinical studies (not developed internally).
Preclinical drug candidate discovered using 3D human liver model
A therapeutic candidate identified and progressed to preclinical development using human 3D liver disease models and multi-omics target discovery workflows.
In-licensed clinical-stage drug candidate (planned Phase 2)
An externally sourced therapeutic candidate intended for progression into Phase 2 clinical studies (not developed internally).
Services
Discovery and progression of therapeutic candidates by combining human 3D tissue models with integrated omics to identify targets and advance compounds to preclinical development.
Discovery and progression of therapeutic candidates by combining human 3D tissue models with integrated omics to identify targets and advance compounds to preclinical development.
Expertise Areas
- 3D human tissue–based drug discovery
- Non-alcoholic steatohepatitis (NASH) disease modeling
- Multi-omics data integration for target discovery
- Preclinical candidate progression
Key Technologies
- 3D bioprinting
- Spheroid and 3D cell culture
- Primary cell co-culture systems
- Next-generation sequencing (NGS)
News & Updates
Press release describing results from 3D human liver models that reproduce MASH (formerly NASH) phenotypes.
Announcement that the company discovered its first drug candidate using 3D bioprinted models and progressed it to preclinical development.
Company-developed therapeutic candidate advanced from discovery to preclinical stage using human 3D liver models and multi-omics target identification.
Press release describing results from 3D human liver models that reproduce MASH (formerly NASH) phenotypes.
Announcement that the company discovered its first drug candidate using 3D bioprinted models and progressed it to preclinical development.
Company-developed therapeutic candidate advanced from discovery to preclinical stage using human 3D liver models and multi-omics target identification.